




Wobble
GENOMICS



DNA
Deoxyribonucleic acid

Company Overview

Wobble Genomics is a biotechnology spin-out from the Roslin Institute, a BBSRC strategically supported institute at the University of Edinburgh, founded in 2021 by Dr Richard Kuo. The company specialises in long-read RNA sequencing and develops integrated biochemical and bioinformatic solutions to improve the sensitivity and efficiency of RNA sequencing for disease diagnostics and biomarker discovery. Its founder previously participated in the Innovate UK ICURe program, a UKRI-backed commercialisation initiative, which supported the transition of the underlying research from academia into a spin-out company.

Key Challenges Addressed

Detecting early disease signals in RNA face significant challenges due to molecule instability, structural complexity, and the low abundance of many clinical-relevant transcripts, which means traditional short-read sequencing can miss critical biomarkers. Wobble Genomics addresses this problem by applying long-read sequencing workflows that capture full-length RNA molecules and preserve subtle variants that are often lost with conventional approaches. By combining optimised web-lab protocols with advanced informatics, the company's technology reveals previously hidden RNA variants, enabling more precise diagnostics, earlier cancer detection and foundations for advanced personalised treatment strategies.



Role of Roslin Innovation Centre

In October 2021, Wobble Genomics joined Roslin Innovation Centre benefiting from its proximity to a vibrant research and academic community, and access to physical space and funding opportunities. With mentorship, infrastructure, and ecosystem support from Roslin Innovation Centre, the company has rapidly advanced its RNA sequencing platform, securing grants, engaging investors and expanding its operations on site as it scales toward commercialisation.

Within this collaborative environment, Wobble Genomics has built strong partnerships across research, industry, and investment networks. Close links with the University of Edinburgh's Roslin Institute and Institute of Genetics and Cancer have helped shape the company's clinical, regulatory, and market strategies, while collaborations with cancer centres and hospitals have generated clinically relevant data that validates the technology and strengthens its adoption.

As a result, Wobble Genomics has evolved from an academic spin-out into a growing biotech company advancing precision medicine, with an RNA sequencing platform that enhances clinical decision-making by enabling earlier interventions and more precise monitoring of treatment in oncology.

